HOUSTON, February 8, 2010 -- Aztec Oil & Gas, Inc. (Pink Sheets: AZGS) previously announced the successful drilling of the Ragle #3 well, which was initially test produced from its deepest secondary target, the Ellenburger formation.  The Ragle #3 has recently been re-completed in the Marble Falls formation and has stabilized at daily rates of approximately 25 BOPD and 50 MCFPD and associated water.  This well has several additional formations up hole that will be developed at a later date, once the Marble Falls formation has been depleted, which is estimated to take several years.

The Ragle #3 is the first of two wells that Aztec has drilled and completed successfully with G&F Oil Company in the Palo Pinto County area of Texas.  “Being able to produce substantial  quantities of oil on a daily basis, as from the Ragle #3 well, keeps Aztec exactly on its path of success with shallow, low risk developmental wells,” stated Aztec President, Waylan Johnson.

Due to the success of the two present Ragle wells, Aztec has contracted to drill two wells on the Wharton and Stanley Projects, located in Palo Pinto and Jones Counties respectively. Similar results to the Ragle wells are estimated, and drilling will commence in the next several weeks.

“Aztec feels it important to point out that after several years of severe drought, almost the entire state of Texas has been inundated with record amounts of rain.  These rains are still occurring and have negatively delayed, but not cancelled, Aztec’s drilling schedules.  In spite of the rains, flooding and mud, Aztec has been able to establish numerous drilling locations in several counties located in areas of prolific shallow production, and get some of its scheduled wells drilled, but not yet completed.  Those wells, and others, will soon be completed and put into production.  At the current commodity prices, being able to bring shallow, Texas, low risk developmental wells, with multiple pay zones, to our niche of the Sponsored Drilling Program industry has helped set Aztec apart from programs focusing on riskier or deeper wells,” added Mr. Johnson. 

About Aztec Oil & Gas, Inc.

Aztec is an oil and gas exploration, development and production company focusing on Texas and numerous areas throughout the U.S.  Its interests are highly diversified as exemplified by its direct corporate participation in two Deep Lake wells in Cameron Parish, Louisiana ranging from 13,600 feet to 14,300 feet in depth versus its corporate participation in three shallow gas wells in Oklahoma of which two are conventional wells, and the third is a horizontal, Coal Bed Methane (CBM) well.

Additional to the foregoing, in 2006 Aztec entered the sponsored drilling program industry and, over the next two and one half years, undertook three small, very limited annual drilling partnerships in Appalachia.  While Aztec’s personnel were experienced in oil and gas exploration and production in many parts of the US, including Texas, sponsored drilling program drilling in Appalachia was recommended to Aztec by several broker dealers and a wholesaler.  The foregoing was, supposedly, because many broker dealers were more familiar with sponsored drilling programs from the Appalachian area.  Aztec intentionally limited its sponsored drilling programs over the subject two and one half years in order to become fully familiar with the nuances of the sponsored drilling program industry before expanding to the Company's full capabilities.  In the summer of 2008, due to what Aztec’s officers felt was a questionable, future outlook for shallow, non-shale gas in the Appalachian region; Aztec publicly announced it was discontinuing natural gas drilling in Appalachia.

Aztec focused all drilling in 2009 in Texas.  In addition to the referenced, initial three small Appalachian drilling partnerships; Aztec has sponsored and closed its VIII A, VIII B and VIII C drilling partnerships.  The seventh drilling partnership, Aztec X A Oil & Gas LP, closed in December 2009, also focuses on drilling in Texas.  Aztec Energy LLC, a wholly-owned subsidiary of Aztec, acts as Managing General Partner of all Aztec drilling partnerships and another wholly-owned Aztec subsidiary, Aztec Drilling & Operating, LLC, is the turnkey drilling contractor and operator for such partnerships.  Aztec owns a 30% interest in all of its drilling partnerships.  In general clarification of its activities, Aztec sponsors low risk, development drilling programs which include significant tax benefits, all of which are sold through FINRA Registered Broker Dealers and Registered Investment Advisors to Accredited Investors.  Aztec’s drilling programs focus primarily on shallow oil drilling, are very unique, and also incorporate a sophisticated exit strategy for investors.

For more information on Aztec Oil & Gas, Inc. please visit http://www.AztecOG.com.

This release/announcement is neither an offer to sell nor a solicitation of an offer to buy securities or participations. This release/document contains certain statements, estimates, and forecasts with respect to future performance and events. All statements other than statements of historical fact included in this release/document, the Memorandum, or the Aztec website, including statements regarding future performance of events, are forward-looking statements. All such forward-looking statements are based on various underlying assumptions and expectations and are subject to risks and uncertainties which could cause actual events to differ materially from those expressed in the forward-looking statements. As a result, there can be no assurance that the forward-looking statements included in this release, the Memorandum, or the Aztec Website will prove to be accurate or correct. In light of these risks, uncertainties and assumptions, the future performance or events described in the forward-looking statements in this release/document, the Memorandum, or the Aztec Website might not occur. Accordingly, investors should not rely upon forward-looking statements as a prediction of actual results. Also, the price Aztec Oil & Gas, Inc. and the other parties involved in any properties receive for the oil and natural gas produced on their properties may be less than quoted NYMEX prices at any given time. Aztec does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events, subsequent circumstances or otherwise.

Contact:

Phoenix IR Associates

Investor Relations

Tony Drake

(281) 579-1602

Shareholders@AztecOG.com

In addition, the Company reported today that it received a $750,000 milestone payment from Amsterdam Molecular Therapeutics B.V. (“AMT”).  This milestone payment was received pursuant to a patent license agreement between the Company and AMT and was triggered by AMT’s filing for marketing approval of Glybera®, a product candidate for the treatment of lipoprotein lipase deficient patients.  AMT announced the regulatory filing with the European Medicines Agency on January 11, 2010.

The Company estimates it finished 2009 with cash and cash equivalents of approximately $4.9 million. The Company intends over the next year to utilize its resources to support continued efforts to monetize certain assets, to realize value from milestone and royalty licensing relationships, and to support product development programs currently underway with commercial and academic partners. Accordingly, based on its current business plans the Company expects its net use of cash during 2010 will not exceed $2 million. The Company’s use of cash in 2010 could be greater if the Company decides to increase spending during the year on new or current programs or other operating activities.

Under the September 2009 asset purchase agreement, the Company sold manufacturing technologies and other adeno-associated viral (AAV) vector technology to Genzyme.  Under the agreement, Genzyme agreed to pay up to $7 million for the assets and the successful transfer of the technology and also agreed to pay a portion of sublicensing revenue received during a specified timeframe and royalties on net product sales of products if Genzyme successfully commercializes products utilizing the acquired Targeted Genetics’ technology.  The Company entered into a non-exclusive patent license agreement with AMT in 2006 which covers Glybera®.  The license agreement provides for AMT to pay royalties on net product sales, milestone payments upon the achievement of certain product development targets and annual maintenance payments.   

“As a result of our significant expense reduction efforts, resolution of liabilities and payments received from partners, the Company has a stable financial footing as we continue to work to maximize the value of existing assets and consider alternatives for advancing the Company,” said B.G. Susan Robinson, President and Chief Executive Officer.  

About Targeted Genetics Corporation

Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative therapies for the prevention and treatment of diseases with significant unmet medical need. To learn more about Targeted Genetics, visit its website at www.targetedgenetics.com.

CERTAIN FORWARD-LOOKING STATEMENTS AND FACTORS THAT MAY AFFECT FUTURE RESULTS

This press release contains certain forward-looking statements concerning the Company’s financial position, results of operations, business strategy, and plans and objectives of management for future operations. These forward-looking statements involve significant risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, readers are cautioned that no assurance can be given that such expectations will prove correct and that actual results and developments may differ materially from those conveyed in such forward-looking statements. Factors that could cause actual results to differ materially from the expectations reflected in the forward-looking statements in this press release include, but are not limited to the risk that the Company will not be able to monetize its assets or enter into one or more strategic transactions, the risk that the Company's current financial resources and future financial resources (if any) will be insufficient to enable the Company to fund continuing operations, the risk that the Company will not receive anticipated future revenue streams, the risk that the Company will run out of cash earlier than expected, the risk that the Company will not receive anticipated milestones or other payments from the Company’s product development partners and collaborators or that the Company’s product development efforts will be unsuccessful, the risks of accomplishing our business plan, the risks associated with the conduct and outcome of the LCA candidate clinical trial and the risk of unforeseen events compromising our cash management plans, as well as those factors described in the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2009, filed November 16, 2009 with the Securities and Exchange Commission.

.

###

Investor and Media Contact:

David J. Poston, Chief Financial Officer

Phone:  206.521.7881

SOURCE: Targeted Genetics

Company Announcement

Living Cell Technologies Receives 10% of US Based Wound Healing Company in Supply and Licence Agreement

9 February 2010: Sydney, Australia, Auckland, New Zealand – Cell implant company Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that it has received 10% ownership of CytoSolv Inc. in exchange for restricted supply of choroid plexus cell clusters from its designated pathogen free pig herd and granting CytoSolv a non-exclusive, non-transferable licence to use its broad choroid plexus patents solely for the purpose of wound healing.

CytoSolv is a newly formed Rhode Island biomedical company developing proprietary technology to address wound healing, initially targeting diabetic ulcers. Its technology involves the delivery of a mixture of wound-healing factors derived from porcine choroid plexus (CP) cells cultured using proprietary techniques. These cells normally secrete a variety of factors into the cerebrospinal fluid that are responsible for growth, differentiation, nurturing and maintenance of the brain. CytoSolv has demonstrated that a topical gel based on a cocktail of these factors accelerates and improves the quality of healing of open skin wounds, and has recently been awarded USD500,000  from the Slater Technology Fund to pursue more advanced pre-clinical development in the year ahead.

Dr Paul Tan, Chief Executive Officer LCT said: “Although this collaboration is outside LCT’s core business of live cell implants, the topical use of secreted products from porcine CP cells offers a potential revenue stream from supply of cells and investment return.  The experienced team at CytoSolv has produced very promising preliminary data, and we look forward to continuing this exciting collaboration.”

-Ends-

For further information: www.lctglobal.com

About Living Cell Technologies: www.lctglobal.com

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases.  The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders.  For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels.  The Company entered clinical trials for its diabetes product in 2007.  For the treatment of Parkinson’s disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain.  LCT’s technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection.  LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT’s business, which can be  identified by the use of forward-looking terminology such as “promising,” “plans,” “anticipated,” “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to,” “potential,” “seeking to,” “goal,” “could provide,” “intends,” “is being developed,” “could be,” “on track,” or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Suite 100 – 11245 Valley Ridge Drive NW, Calgary, AB, T3B 5V4 * Tel (403) 200 1033

NEWS RELEASE

February 8, 2010                                                                          CYLC Pink Sheets – OTC

                                                                                      G7Q.F – Frankfurt Stock Exchange

COUNTY LINE ENTERS LETTER OF INTENT FOR MINING PROPERTY

County Line Energy Corp. (the “Company”), is pleased to announce that it has signed a Letter of Intent to enter into an agreement with 1^st Light Resources in order to option 100% of their Dog Lake mining property in Ontario, Canada. The Company is excited to be in the acquisition process due to the “high potential” of the Dog Lake property.  

The terms of optioning the Dog Lake project, as outlined in the Letter of Intent, include a total issuance of 5,000,000 shares of the Company (CYLC) to 1^st Light Resources. More details of the agreement will be forthcoming once the agreement is finalized and signed.

For further information on the Company, please call our office at (403) 200-1033 or visit our web site at www.countylineenergy.com

 On behalf of the Board,

Harry Bygdnes, BSc.

President

 ________________________________________________________________________

This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

 Connectyx, Announces MedFlash® Advertising Contract with SkyMall Inc.   

PALM CITY, FL -- /PinkSheets-FirstCall/February 8, 2010 -- Connectyx Technologies Holdings Group Inc. (Pink Sheets:CTYX.PK) has signed an advertising contract with SkyMall Inc.SkyMall produces thefamiliar, quarterly in-flight publication that is distributed in major airlinesseat pockets. SkyMall has an annual circulation of approximately 20 millioncopies. The advertisement featuring the MedFlash® Personal Health Manager (PHM) will be located directlyopposite the table of contents in the front section of the magazine.  Look for the advertising to begin in theApril issue and run for at least three months.  MedFlash advertising will also be featured on theSkyMall website.

“This is a great opportunity for us to buildthe MedFlash brand as the leader in providing easy and secure tools for themaintenance of personal health information. Adding SkyMall’s millions of readers to our recent sponsorship ofDerrike Cope’s NASCAR team, The Orlando Magic “Sixth Man Fan” promotion and ourrecent sale to Walgreens Orlando market creates strong brand awareness forMedFlash.  We want to be the first placepeople go when they decide to take control of their personal health information”.Stated Ronn Schuman, Connectyx President.

SkyMall is a multi-channel marketer, offering highquality products through its major airline catalog and web site, skymall.com.The SkyMall catalog is seen by approximately 88% ofall domestic air passengers reaching more than 600 million air travelers annually.SkyMall also offers participants a turn-key call center, merchandise andfulfillment solutions for loyalty marketing programs.

About Connectyx TechnologiesHoldings Group Inc.

Connectyxprovides unique products for the healthcare market including, MedFlash, theelectronic Personal Health Manager (PHM). Compatible with Google Health andMicrosoft's Health Vault, The MedFlash PHM is an easy to use Personal Healthand Lifestyle Manager that is accessible using a powerful web portalsuite.  The MedFlash PHM also features a24/7/365 call center, a USB flash drive and our (soon to be released) smartphone applications. The MedFlash PHM provides member benefits including instantaccess to your Emergency Medical Profile and Personal Health Record in theevent of an accident or a medical emergency. Whether traveling, at work, or athome, First Responders have an invaluable advantage when they have access tothis time critical information. Far more than just an emergency flash drive,The MedFlash PHM can be accessed on any computer, securely and with completeprivacy.

MedFlashmembers have the ability to arrive at their Doctors offices with theirpaperwork pre-printed and ready to go. Prescriptions, Insurance information andadvance directives are available at a moment's notice through the MedFlash PHM forthe physician's reference. Those are just a few of the time saving and riskmitigation features the MedFlash PHM provides. Connectyx products are developedwith the needs of Patients, Families, Doctors and First Responders in mind. Formore information, please visit our websites at: www.connectyx.com and www.medflash.com

SafeHarbor Act:

This release includes forward-lookingstatements made pursuant to the safe harborprovisions of the Private Securities Litigation Reform Act of 1995 thatinvolves risks and uncertainties including, but not limited to, the impact ofcompetitive products, the ability to meet customer demand, the ability tomanage growth, acquisitions of technology, equipment, or human resources, theeffect of economic business conditions, and the ability to attract and retainskilled personnel. The Company is not obligated to revise or update anyforward-looking statements in order to reflect events or circumstances that mayarise after the date of this communication.

Contacts:

Public Relations:

Big Apple Consulting USA

407-389-5900

Source: Connectyx Technologies Holdings Group, Inc. 

ID Watchdog Announces Revolutionary New Productthat Provides Instant Feedback on ID Theft

idCHECK Makes Identity Theft Analysis Quick, Easy,and Affordable for Every Individual – and Is Available for Free for a LimitedTime

DENVER-- ID Watchdog, Inc. (TSX.V:IDW)(OTCQX:IDWAF), provider of the most comprehensive identity theft protection andresolution services in the market today, unveiled its revolutionary idCHECKproduct.

For a limited time, the Company is offeringconsumers the opportunity to use the product for free*. To get a free idCHECK,go to www.idwatchdog.com/idcheck and use the promo code “idcfree01_pr.”

idCHECK is the first identity theft protectionproduct that allows consumers to instantly determine whether an organizedidentity theft network may have accessed their personal data. idCHECK works byscanning thousands of consumer databases, most of which aren’t easily accessedby consumers, to expose evidence of identity theft. Results are presented on anintuitive dashboard using a simple coding system, providing the consumer withan easy to understand assessment of his or her risk, as well as ongoing accessto additional identity theft tools, resources, and action plans.

“Identity theft impacts millions of consumers everyyear, but often goes undetected for months or even years, giving thieves plentyof time to do serious damage. Because identity thieves don’t discriminate, webelieve that every consumer should take proactive steps to protect his orherself and loved ones from identity theft. As the industry’s first tool thatcan provide consumers with immediate answers, idCHECK cuts through identitytheft marketing hype with the simplest and most effective path to affordablepeace of mind,” said Daniel Mohan, President and Chief Operating Officer of IDWatchdog.

Offered in single-use units, idCHECK deliverslow-cost access to large amounts of valuable personal data, patent-pendinganalytics to make sense of the data, and an opportunity for consumers to“test-drive” a monitoring service before deciding whether they’d benefit fromcomprehensive monthly identity monitoring products.

"We are the only identity theft serviceprovider that has the degree of access into data aggregators necessary to makethis critical consumer-facing product possible," said Nick Bryla, VicePresident of Product Management and Marketing at ID Watchdog. "Thisaccess, combined with analytics developed by our Victim Resolution Group basedon thousands of real identity theft cases, represents a defendable competitiveadvantage and we intend to make the most of this position."

ID Watchdog is finalizing agreements withtraditional brick-and-mortar retailers and online stores to carry the product,as well as with associations and affinity groups seeking to offer additionalbenefits to their memberships.

* idCHECK is available to U.S. Residents only.

About ID Watchdog, Inc.

Headquartered in Denver, ID Watchdog is the onlyidentity theft detection and resolution company that provides patent-pending,three-tiered comprehensive monitoring, detection and resolution for identitytheft. Unlike its competitors, ID Watchdog proactively detects identity theftproblems at their source. Developed with the assistance of national consumeradvocacy groups; the U.S. Postal Service; federal, state and local law enforcementagencies, and state and local Attorneys General, ID Watchdog's service isfocused on detecting the source of identity theft problems as early aspossible, in as many places as possible, and taking immediate corrective actionon behalf of the consumer.

For comprehensive investor relations material,including fact sheets, research reports, interviews and video (when available),please follow the appropriate link: Investor Community, Investor Relations Portal, and Corporate Overview Video

For additional information, please visit IDWatchdog’s corporate website: www.IDwatchdog.com.

Forward-Looking Statement

This news release includes certain"forward-looking statements" within the meaning of the United StatesPrivate Securities Litigation Reform Act of 1995 which address future eventsand conditions which are subject to various risks and uncertainties. The actualresults could differ materially from those anticipated in such forward-lookingstatements as a result of numerous factors, some of which may be beyond theCompany's control. Although the Company believes that its expectationsreflected in these forward-looking statements are reasonable, no assurance canbe given that actual results will be consistent with these forward-lookingstatements. Important factors that could cause actual results to differ fromthese forward-looking statements are disclosed in the company's filings withCanadian regulators at www.sedar.com. ID Watchdog assumes noobligation to update the forward-looking statements of management beliefs,opinions, projections, or other factors should they change.

Neither TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSX VentureExchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts

Company Contact:


ID Watchdog, Inc.


Justin Yurek, Senior Vice President


303-339-8011


InvestorRelations@idwatchdog.com


www.idwatchdog.com


or


Financial Communications Contact:


Trilogy Capital Partners


Darren Minton, Executive Vice President


Toll-free: 800-592-6067


info@trilogy-capital.com

Source: ID Watchdog, Inc.

In addition to the operations of the target company, the acquisition would include land, buildings and equipment.  Tesoro believes that the acquisition will add revenue, broaden the product base and expand the geographical coverage of its current operations.  The target company has a long track record of stable revenue and positive EBITDA.

Information concerning the company is available on our website at http://tesoroenterprises.us or by contacting us at 191 Post Road West, Westport, CT 06880.